LG CNS has invested 10 billion KRW in Chah Biotech to enhance digital healthcare services through AI and big data integration.

Information on the Target

Chah Bio Group is a comprehensive biomedical and healthcare organization that encompasses various sectors, including hospitals, pharmaceuticals, biotechnology research, and healthcare services. The group's core company, Chah Biotech, also operates several affiliated enterprises such as Chah AI Healthcare, CMG Pharmaceuticals, Chah Vaccine Institute, Chah Healthcare, and Chah Meditech. In addition to its domestic operations, Chah Bio Group has extended its reach internationally, running healthcare ventures in the United States, Singapore, Australia, and Japan.

Industry Overview in the Target’s Specific Country

South Korea's healthcare and biotechnology sector has experienced significant growth in recent years, driven by advancements in medical technology and an increasing focus on research and development. The government has prioritized investments in healthcare innovations, aiming to position the country as a leader in digital health and AI-based medical solutions.

The rise of telemedicine and connected healthcare services has transformed patient care models, particularly post-COVID-19. These changes have prompted healthcare